CN103747692A - Monounsaturated fatty acid for preventing and/or treating skin complexion imperfections - Google Patents

Monounsaturated fatty acid for preventing and/or treating skin complexion imperfections Download PDF

Info

Publication number
CN103747692A
CN103747692A CN201180064169.8A CN201180064169A CN103747692A CN 103747692 A CN103747692 A CN 103747692A CN 201180064169 A CN201180064169 A CN 201180064169A CN 103747692 A CN103747692 A CN 103747692A
Authority
CN
China
Prior art keywords
skin
monounsaturated fatty
fatty acids
salt
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180064169.8A
Other languages
Chinese (zh)
Inventor
奥德丽·格尼什
伊莎贝尔·卡斯蒂埃尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
LOreal SA
Original Assignee
Nestec SA
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA, LOreal SA filed Critical Nestec SA
Publication of CN103747692A publication Critical patent/CN103747692A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013—Other fatty acid esters, e.g. phosphatides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/48—Moist feed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the oral cosmetic or nutraceutical use of an effective amount of at least one monounsaturated fatty acid, of a salt thereof and/or of an ester thereof, as an active agent for treating and/or preventing skin complexion imperfections.

Description

For preventing and/or treating the monounsaturated fatty acids of skin complexion defect
Technical field
The present invention relates to the field for beautification product and/or skin disease goods and the food supplement of the nursing skin colour of skin.
More specifically, the present invention proposes a kind of purposes that is used for the treatment of and/or prevents the novel active agent of the aesthetic defect of skin of skin complexion.The invention still further relates to and be applicable to treat and/or prevent the defect of skin complexion and the method for uniform defect.
Background technology
Many factors can cause the defect in the colour of skin of skin and skin.These skin complexion defects are to cause consulting reason day by day frequently in beauty parlor or skin disease clinic.
Easily affecting in the external factor of skin complexion, that can mention has: be exposed under sunlight, be exposed to variations in temperature and/or humidity change under and contact stain thing or smoke from cigarette.In the internal factor that affects skin complexion, that can mention has: pressure, fatigue, hormone change, epidermis dewaters, the excessive secretion of barrier function damage, aging or the sebum of skin.
In addition, inherent cause can affect the individual susceptibility on the easy external condition that affects skin complexion.
Therefore, certain race, for example, the race in Asia source or source, Africa, the more responsive and skin complexion that has of the skin texture that has such as pollute and the external condition of smoke from cigarette under more easily or impaired more consumingly.This situation for the elderly is also like this.
These various factors can make the colour of skin fuzzy, inhomogeneous, dim, pale or yellow and bring or promote the appearance of skin blemishes or dermatodyschroia.
In its slight form, these defects relate to almost everyone, and they are the most frequent in the age in puberty.But they can appear at early to age of 7 years old to 9 years old and can continue until 40 years old, and especially can continue until 60 years old.Therefore, even after 25 years old, have skin defect (especially on the face) as coarse, dim and/or the inhomogeneous colour of skin be common.In its slight form, these skin defects can be mainly by fuzzy, the dim and/or inhomogeneous colour of skin with have dermatodyschroia or flaw manifests.
In its most serious form, these damages can have abrasive psychosocial consequence once in a while, and for affected individual thus, this can cause lonely or even dejected or unemployment.
Therefore, conscientiously need can prevent, reduce or treat these skin complexion defects.
Also need to produce effectively and the novel active agent of beneficial effect skin complexion defect.
Summary of the invention
The object of the invention is to meet these needs.
Therefore, according to first aspect, the present invention relates to the oral or nutrition beautifying use of at least one monounsaturated fatty acids, its salt and/or its ester of effective dose, described monounsaturated fatty acids, its salt and/or its ester are as the activating agent that treats and/or prevents skin complexion defect.
Monounsaturated fatty acids has been described for multiple use, such as, the treatment of the moisturizing of the dry skin in patent EP0709084 or the dandruff in patent EP0116439 and itching of the scalp.
Patent WO01/08651 has described the composition that comprises petroselic acid, and said composition is for controlling the secretion of sebum and making skin complexion brightening.
United States Patent (USP) 4097604 points out that the salt of various aliphatic acid is that effectively therefore it can reduce the incidence of disease of these bacteriums when periodontitis is shown effect for Oral Pathogens.Therefore the function of these aliphatic acid is limited to oral cavity flora.
Patent EP0355842 has described the Pigmented face cream causing due to melanic excessive generation for preventing, and described face cream can contain petroselic acid.
Patent EP1013178 has described the purposes of petroselic acid as antiphlogistic, and is used for the treatment of the purposes of the sign (such as wrinkle, cutis laxa and senile plaque expelling (senescence mark)) of skin aging.
Patent WO99/47110 has described the beauty method that uses petroselic acid to be used for the outward appearance of improving skin.
Patent US6022890 has described the composition that comprises acceptable carrier in 'alpha '-hydroxy acids, petroselic acid and beauty treatment.
But these documents all do not propose: to the individuality of needs use the monounsaturated fatty acids of effective dose, especially petroselic acid susceptible of proof is especially effectively for preventing and/or treating skin complexion defect.
Inventor can explain, monounsaturated fatty acids, petroselic acid especially cause perfectly restoring normal skin tissue in homeostasis, and this normal skin tissue presents glossiness, young and colour of skin healthy appearance.
The individuality of therefore, treating according to the present invention is advantageously found out the minimizing of its skin complexion defect or is even disappeared.Skin complexion can become evenly, and there is no the outward appearance of dermatodyschroia or dimness and there is no flaw.
In addition, advantageously, the present invention can give skin, especially skin of face glossiness and general the outward appearance of radiance.
For purposes of the present invention, according to the present invention, that term " skin " is intended to represent is individual, all skins of people especially, and the skin of face, neck and neckline more specifically.Term " skin " comprises the surface that chaeta covers.
Preferably, the present invention is more specifically applicable to the skin of nursing face, neck and neckline, is preferred for nursing skin of face.
According on the other hand, theme of the present invention is a kind of oral cosmetic treatment that is used for the treatment of and/or prevents the individual skin complexion defect of needs, and described method comprises at least one step that at least one monounsaturated fatty acids of effective dose, its salt and/or its ester is applied to described individuality.
The present invention advantageously can prevent and/or treat skin complexion defect.
According to an embodiment, the present invention advantageously can prevent and/or treat fuzzy, dim and/or inhomogeneous skin complexion.
According to another embodiment, the present invention advantageously can prevent and/or treat the skin complexion defect that is selected from acne, dry spot (dry patch), dermatodyschroia and blackhead.
According to another embodiment, according to purposes of the present invention, advantageously can prevent and/or treat pale, jaundice or the even ill colour of skin.
According to monounsaturated fatty acids of the present invention, must use with effective dose, that is, make aliphatic acid for waiting to prevent and/or skin complexion Flaw display to be treated goes out the amount of its surfactant properties.
For purposes of the present invention, term " prevention " refers to that occurrence risk or the probability of happening of given phenomenon (that is, skin complexion defect of the present invention) are reduced to lighter degree.
monounsaturated fatty acids
For purposes of the present invention, term " monounsaturated fatty acids " refers to the aliphatic acid of the hydrocarbyl chain that only comprises two keys.
Such aliphatic acid contains the aliphatic acid of long hydrocarbyl chain more specifically.The monounsaturated fatty acids that is applicable in the present invention using especially comprises and contains 12 monounsaturated fatty acids to the hydrocarbyl chain of 22 carbon atoms.
The monounsaturated fatty acids that is applicable in the present invention using can be used with the form of acid or salt, or alternatively with form, especially fatty acid amide and the ester class of derivative.
When they are the form of salt, the monounsaturated fatty acids of the present invention upper acceptable salt of improving looks more specifically, that is, and inorganic salts, such as, ammonium salt, alkali metal (such as, lithium, potassium or sodium) salt, alkaline-earth metal (such as, magnesium or calcium) salt, or aluminium salt.
Particularly, the applicable monounsaturated fatty acids using can be the form of calcium salt in the present invention.
When they are the form of ester, monounsaturated fatty acids of the present invention can utilize the glycerine of single acyl, two acyls or trigalloyl form; Such as the alcohols of methyl alcohol and ethanol; Carbohydrate (especially monose or disaccharide), tocopherol, tocotrienol, such as the sterol of cholesterol or such as the phytosterol of cupreol; Or aliphatic acid, especially C 8to C 18aliphatic acid carry out esterification.
Should be appreciated that, consider that the final use of the composition that comprises these materials is selected monounsaturated fatty acids of the present invention.
Monounsaturated fatty acids according to the present invention is by oral administration.
Monounsaturated fatty acids of the present invention, its salt and/or its ester can be in oral compositions, wherein, the content of described monounsaturated fatty acids, its salt and/or its ester is: daily dose is from 0.5mg/ days to 2500mg/ days and especially in the scope from 5mg/ days to 500mg/ days.
In the monounsaturated fatty acids that is applicable in the present invention using, be especially applicable to using oleic acid or petroselic acid.Petroselic acid is particularly useful for the present invention.
According to a modification of the present invention, monounsaturated fatty acids is used with the form separating, that is, and and extracting then and use from the source of monounsaturated fatty acids.
According to another modification of the present invention, monounsaturated fatty acids is used with the plant extracts such as oily.
Therefore, the invention particularly relates to the oily beautifying use that is rich in monounsaturated fatty acids of the present invention, be especially rich in the oily beautifying use of petroselic acid.
The oils that is rich in petroselic acid is more specifically selected from Umbelliferae (Umbellifera) vegetable oil.
Term " is rich in the oils of petroselic acid " and refers to the oil that comprises at least 40% petroselic acid.
Samphire is that its flower is plant that umbrella shape is arranged, and the species that are rich in especially petroselic acid are Umbelliferae (Umbelliferea-Apiacea) plant and five Solanaceaes (Araliaceae) plant.The plant that deadly carrot belongs to (Thapsia) is also the source (Avato etc., Lipids, 2001,36,845) of petroselic acid.
The species that preferably use are in the present invention coriander, tuberous chervil (chervil), carrot, celery, cumin (cumin), Caraway (caraway), parsley and dill (dill).
The samphire oil used according to the present invention can extract from the seed of samphire, for example, by milling or suppressing, refining subsequently.
The petroselic acid content that samphire oil has changes according to the samphire seed extracting.For same samphire, petroselic acid content also changes according to the country of origin of samphire and the leaching process that completes substantially.
Abundant compound (approximately 48%) (Tsevegsuren etc., Lipids, 2004,39,571) in the oil of petroselic acid or a kind of seed from safflower geranium wilfordii (Gernium sanguneum).
According to an embodiment, more specifically, the monounsaturated fatty acids of considering is in the present invention petroselic acid.
Particularly, petroselic acid can be used with the form of samphire oil or safflower geranium oil.
According to another embodiment, the samphire oil that the present invention considers can be selected from the seed oil of coriander, the seed oil of tuberous chervil, the seed oil of carrot, the seed oil of celery, the seed oil of cumin, seed oil, the seed oil of parsley and the seed oil of dill and their mixture of Caraway.
purposes
The present invention can improve, unify or recover the colour of skin of skin.
According to a beauty treatment embodiment, the present invention is intended to prevent and/or treat skin complexion defect.
For purposes of the present invention, term " skin complexion defect " refers to the damage of the natural look of healthy skin.
The skin complexion defect of considering in the present invention does not comprise the skin injury being produced by the inflammatory phenomena such as inflammation redness.
The skin complexion defect of considering in the present invention does not comprise the skin defect associated with melanic excessive generation.
The skin complexion defect of considering in the present invention does not comprise such as skin surface defect coarse or cracking.
For purposes of the present invention, skin complexion defect does not comprise colour of skin luminance defects, and purposes of the present invention is not intended to brightening skin complexion or bleaching skin.
More specifically, the skin complexion defect of considering in the present invention can especially be selected from fuzzy skin, dim skin, skin or tool skin defective or the dermatodyschroia of the inhomogeneous colour of skin.
For purposes of the present invention, term " skin blemishes " refers to the tumour, blackhead or the scar that have dermatodyschroia or there is no dermatodyschroia.
More specifically, use the gloss that can demonstrate the colour of skin according to monounsaturated fatty acids of the present invention.
For purposes of the present invention, statement " demonstrating the gloss of skin complexion " under any circumstance can not liken the effect that is intended to brightening skin complexion to.For purposes of the present invention, the gloss of skin complexion shows the natural gloss of the skin complexion feature of youth, healthy skin.
Therefore, the present invention can provide fuzzy and less gloomy and more vernicose skin complexion less dimness, less.
formulation
Composition according to the present invention can be taken orally.According to composition of the present invention, can be according to the normal any formulation used of use approach.
Composition according to the present invention comprises on physiology or pharmaceutically acceptable medium.
The advantage of oral route and/or parenteral route is more fully to act in the deep layer of whole skin and skin.
Term " Orally administered composition " refers to, for example, nourishes composition, alimentation composition or medicinal make-up composition, and said composition comprises according at least one monounsaturated fatty acids of the present invention, its salt and/or its ester.
For being applicable to the composition of oral administration, preferably use absorbable carrier.According to the types of compositions of considering, absorbable carrier can have different character.
In order to take in, Orally administered composition especially multiple embodiments of food supplement is feasible.
By for arbitrary conventional method for the preparation of for example drinkable solution, sugar coated tablet, gel capsule, gel, emulsion, Swallow tablet or chewable tablets, capsule (especially soft capsule and hard shell capsules), dissolved particles, syrup, solid food or liquid food and slowly-releasing hydrogel known to those skilled in the art, can carry out the preparation of this Orally administered composition.
The oral supplement of tablet, gel capsule or ordinary lozenges, suspension, dry type oral supplement and liquid form is for example suitable as food carriers.
Particularly, according to activating agent of the present invention, can be merged in any type of food supplement or enriched food, for example, food bar or compacting or loose powdered.This powder can water, soda, dairy products or soybean derivatives dilution, maybe can join in food bar.
According to one preferred embodiment, according to the composition of oral administration of the present invention, can be formulated into coating tablet, gel capsule, gel, emulsion, tablet, capsule, hydrogel, food bar, form compression or loose powdered, suspension or liquid solution, cake, acidified milk, leavened cheese, chewing gum, toothpaste or spray liquid.
The example of applicable food carriers comprises breast, Yoghourt, cheese, acidified milk, the fermented product based on milk, ice cream, based on oral supplement fermentation or the goods of unfermentable cereal, powder, the baby formula based on milk, the animal feed that is particularly useful for pet, tablet or ordinary lozenges, liquid bacterial suspension, dry type oral supplement and liquid form.
Described Orally administered composition can be anhydrous form or moisture form according to beautifying skin indication.
Can be by excipient and formulated for such Orally administered composition or the common composition of food supplement according to activating agent of the present invention, the i.e. especially composition of fat constituent and/or water-based, wetting agent, thickener, anticorrisive agent, skin texture agent (texture agent), flavoring agent and/or covering, antioxidant, anticorrisive agent and the colouring agent of described common composition, these materials are common in food department.
For Orally administered composition and in particular for the formula reagent of food supplement with excipient is well known in the art and will not be the theme of describing in detail herein.
Particularly, according to composition of the present invention, can be the food compositions for human consumption.Said composition can be especially following situation: wholefood, beverage, mineral water, soup, dietary supplements and the substitute food product of nutrition, nutrition bar, cake, based on fermentation or unfermentable dairy products, Yoghourt, powder, EA goods, baby's composition and/or the child's composition based on newborn, the goods based on fermentation or unfermentable cereal, ice cream, chocolate, coffee or be for example " cooking " goods of mayonnaise, catsup or mayonnaise.
According to composition of the present invention, can also be used for animal, be especially for example the pet of cat and dog, and can be formulated for the form of feed or the food supplement of animal.
other activating agent
According to monounsaturated fatty acids of the present invention, can be advantageously use with the other activating agent combination of cosmetic activity agent or pharmaceutically active agents especially.
Advantageously, so other cosmetic activity agent or pharmaceutically active agents can be for to skin, hair, eyelashes, chaeta and/or scalps and preferably skin is applied to aesthetic nursing or hygiene effect.
By those skilled in the art, chosen the other activating agent of the effect of not damaging monounsaturated fatty acids of the present invention.
Especially, be applicable in the present invention the other activating agent that uses optional from for treating and/or preventing Oily or being easy to the activating agent of the skin of oiliness.
According to another embodiment, according to of the present invention, for preventing and/or treating dermopathic activating agent, can combine with microorganism.
About operable other activating agent, that can mention has:
-vitamin, for example vitamin A, vitamin B5, pyridoxamine, VB8, vitamin C, vitamin D, vitamin E or nicotinic acid (vitamin B3 or nicotinic acid),
-antioxidant, for example: curcuminoid; Carotenoid, especially (be for example selected from beta carotene, lycopene and its derivative, All-cislycopene or lactic acid lycopene (lactolycopene)), astaxanthin, zeaxanthin and lutein, or the carotenoid of the compound that contains zeaxanthin and lutein (for example, matrimony vine, lactic acid matrimony vine (lactowolfberry)); Polyphenol compound, flavonoids is the former corn flower phenol of catechin, aurantiamarin, OPC, anthocyanidin and PCO(oligomer for example); Ubiquinone; The coffee-extract that contains Polyphenols and/or Diterpenes; Chicory extract; Ginkgo (Ginkgo biloba) extract; Be rich in the grape extract of OPC; Pimento extract; Extract of soybean; Cocoa or cocoa breast; Pomegranate; Remaining mandarin orange (Emblica);
-mineral matter, for example zinc, calcium, magnesium, copper, iron, iodine, manganese, selenium or chromium (III),
-sugar,
-amino acid, especially sulfur-containing amino acid and containing selenoaminoacid, described sulfur-containing amino acid is for example glutathione precursor, taurine,
-ternary and hexa-atomic poly-unrighted acid,
-probiotic, is especially selected from from the chewing gum of for example glucose, galactolipin, wood sugar, maltose, sucrose, lactose, starch, xylan, hemicellulose, synanthrin, gum arabic type or the compound sugar that their mixture is made.More specifically, this oligomer comprises at least one FOS.More specifically, this probiotic can comprise the mixture of FOS and synanthrin,
-phytosterol, for example resveratrol,
-aurantiamarin, and
-their mixture.
According to one preferred embodiment, according to monounsaturated fatty acids of the present invention, its salt and/or its ester can be other with at least one active cosmetic agent be used in combination, this other active cosmetic agent can especially be selected from vitamin B3, vitamin B5, pyridoxamine, VB8, vitamin C, vitamin E or nicotinic acid, carotenoid, curcuminoids, nicotinic acid, flavonoids, one or more divalence mineral cations, bacterium or bacterial extract are (from non-photosynthetic, the der Pilz of non-solid (non-fructifying)), probiotic micro-organisms, especially lactic microorganisms, the mixture of the mixture of probiotic nutrient or probiotic micro-organisms and/or probiotic nutrient.
Particularly, can use antioxidant compound, this antioxidant compound comprises vitamin C and vitamin E, for example, with at least one carotenoid, especially (be selected from beta carotene, lycopene and its derivative, All-cislycopene or lactic acid lycopene), astaxanthin, zeaxanthin and lutein or contain zeaxanthin and the carotenoid of the compound of lutein (for example, matrimony vine, lactic acid matrimony vine); Flavonoids (for example catechin, aurantiamarin, OPC and anthocyanidin); Resveratrol; Cocoa or cocoa breast; Pomegranate and remaining mandarin orange.
Composition of the present invention can also contain with various forms of one or more divalence mineral cations.
Therefore, divalence mineral cation can be the form of the mineral of anhydrous or hydration or the complex compound of organic salt or chelating.These salt can be for example carbonate, bicarbonate, sulfate, glycerophosphate, chloride, nitride, acetate, hydroxide, oxide, Alpha-hydroxy hydrochlorate (citrate, tartrate, lactate, malate) or tartaric acid salt, or amino-acid salt (aspartate, arginine salt, fumarate) or soap (palmitate, oleate, caseinate, behenate) alternatively.
Divalence mineral cation can be selected from manganese, copper and/or zinc or be selected from alkaline-earth metal.As the alkaline-earth metal that can use in the present invention, can should be mentioned that barium, calcium, magnesium, strontium and/or beryllium.
Advantageously, divalence mineral cation, especially alkaline-earth metal, used with the form of salt in the present invention.Particularly, this salt can be selected from nitrate, citrate, chloride, gluconate, sulfate, lactate and/or acetate.
Divalence mineral cation can also be used with the form of the complex compound of chelating, is especially chelated to crystalline protein or Ionized albumen.
Divalence mineral cation for example can also be, by the particular form of microorganism (, saccharomycete is as selenium yeast) storage.
According to another embodiment, composition of the present invention can containing just like according to uncle's Jie Shi systematic bacteriology handbook (Bergey ' s Manual of Systemic Bacteriology, the 3rd volume, the 23rd part, the 9th version, 1989) classification non-photosynthetic, the non-solid der Pilz that limit, or from the bacterial extract of non-photosynthetic, non-solid trichobacteria.
Can should be mentioned that especially: belong to the bacterium of Beggiatoales (Beggiatoales), and especially belong to the bacterium that Beggiatoa (Beggiatoa) belongs to.In addition, can also should be mentioned that belonging to Vitreoscilla (Vitreoscilla) belongs to, it is similar to Beggiatoa and belongs to.In operable bacterium, for example, can should be mentioned that class shellfish Salmonella Vitreoscilla (Vitreoscilla beggiatoides, ATCC43181) and white sulphur silk bacterium (Beggiatoa alba, ATCC33555), preferably use the extract of wire Vitreoscilla (Vitreoscilla filiformis), especially strains A TCC15551, its metabolin and its part (fraction) can be used.
Composition of the present invention can also comprise the mixture of at least one probiotic micro-organisms, probiotic reagent or probiotic micro-organisms and the mixture of probiotic reagent.
The concrete example that is applicable in the present invention the probiotic micro-organisms using is bifidobacterium adolescentis (Bifidobacterium adolescentis), animal bifidobacteria (Bifidobacterium animalis), bifidobacterium bifidum (Bifidobacterium bifidum), bifidobacterium breve (Bifidobacterium breve), bifidobacterium lactis (Bifidobacterium lactis), bifidobacterium longum (Bifidobacterium longum), bifidobacterium infantis (Bifidobacterium infantis), bifidobacterium pseudocatenulatum (Bifidobacterium pseudocatenulatum), lactobacillus acidophilus (Lactobacillus acidophilus, LC1, NCFB1748), Lactobacillus amylovorus (Lactobacillus amylovorus), Lactobacillus casei (Lactobacillus casei, Shirota), Lactobacillus rhamnosus (Lactobacillus rhamnosus, GG strain), Lactobacillus brevis (Lactobacillus brevis), Lactobacillus crispatus (Lactobacillus crispatus), Lactobacillus delbrueckii breast subspecies (Lactobacillus delbrueckii subsp.bulgaricus, lactis), lactobacillus fermenti (Lactobacillus fermentum), Lactobacillus helveticus (Lactobacillus helveticus), chicken lactobacillus (Lactobacillus gallinarum), lactobacillus gasseri (Lactobacillus gasseri), Yue Shi lactobacillus (Lactobacillus johnsonii), lactobacillus paraceasi (Lactobacillus paracasei), lactobacillus plantarum (Lactobacillus plantarum), lactobacillus reuteri (Lactobacillus reuteri), Lactobacillus rhamnosus (Lactobacillus rhamnosus), Lactobacillus salivarius (Lactobacillus salivarius), digestion lactobacillus (Lactobacillus alimentarius), lactobacillus curvatus (Lactobacillus curvatus), Lactobacillus casei cheese subspecies (Lactobacillus casei subsp.casei), Lactobacillus saki (Lactobacillus sake), Lactococcus lactis (Lactococcus lactis), enterococcus faecalis (Enterococcus faecalis) or VREF (Enterococcus faecium), Lactococcus lactis (Lactococcus lactis, lactic acid subspecies or butterfat subspecies), Leuconostoc mesenteroides dextranicum (Leuconostoc mesenteroides subsp.dextranicum), Pediococcus acidilactici (Pediococcus acidilactici), synanthrin lactobacillus (Sporolactobacillus inulinus), saliva chain coccus thermophilous subspecies (Streptococcus salvarius subsp.thermophilus), streptococcus thermophilus (Streptococcus thermophilus), Staphylococcus carnosus (Staphylococcus carnosus), staphylococcus xylosus (Staphylococcus xylosus), saccharomycete (Saccharomyces, brewer's yeast (Saccharomyces cerevisiae) or saccharomyces boulardii (Saccharomyces boulardii)), bacillus (Bacillus cereus var.toyo) or bacillus subtilis (Bacillus subtilis), bacillus coagulans (Bacillus coagulans), bacillus licheniformis (Bacillus licheniformis), Escherichia coli (Escherichia coli) bacterial strain nissle, Fei Shi bacterium acidi propionici (Propionibacterium freudenreichii) and their mixture.
These microorganisms can be made into the form (i.e. dry form) of powder, or the form of suspension or solution.
More specifically, these microorganisms can be selected from genus lactubacillus and/probiotic micro-organisms of microorganism, its part and/or its metabolin of Bifidobacterium.As the explanation of these microorganisms, can should be mentioned that especially: Yue Shi lactobacillus, lactobacillus reuteri, Lactobacillus rhamnosus, lactobacillus paraceasi, Lactobacillus casei, bifidobacterium bifidum, bifidobacterium breve, bifidobacterium longum, animal bifidobacteria, lactic acid Bifidobacterium, bifidobacterium infantis, bifidobacterium adolescentis and bifidobacterium pseudocatenulatum and their mixture.
Be particularly suitable for use species for according to budapest treaty on June 30th, 1992, on January 12nd, 1999, on April 15th, 1999, on April 15th, 1999 and on June 7th, 2005, at Institute Pasteur (28, rue du Docteur Roux, F-75024Paris cedex15) preserving number of preservation is CNCM I-1225, CNCM I-2116, CNCM I-2168, the Yue Shi lactobacillus of CNCM I-2170 and CNCM I-3446, lactobacillus paraceasi, bifidobacterium adolescentis, bifidobacterium longum and lactic acid Bifidobacterium NCC2818(are also referred to as Bb12ATCC27536), and bifidobacterium longum belongs to (BB536).The bacterial strain of lactic acid Bifidobacterium (ATCC27536) can come from Hansen(Chr.Hansen A/S, 10-12Boege Alle, P.O.Box407, DK-2970, Hao Si Huoermu, Denmark).
According to a specific embodiment of the present invention, said composition comprises at least two kinds of different microorganisms, especially probio of these microorganisms, and/or metabolin and/or its part.These microorganisms can according to character (for example, bacterium and fungi), alternatively according to their section, they genus or their kind or only by their strain, distinguish.
The probiotic reagent that is applicable in the present invention using can be selected from compound sugar, and this compound sugar for example originates from the chewing gum of glucose, galactolipin, wood sugar, maltose, sucrose, lactose, starch, xylan, hemicellulose, synanthrin, gum arabic type or their mixture.More specifically, this compound sugar comprises at least one fructose oligosaccharides.More specifically, this probiotic can comprise the mixture of fructose oligosaccharides and synanthrin.
Composition of the present invention can also advantageously contain the poly-unrighted acid that is especially selected from omega-fatty acid and ω-6 aliphatic acid.
Particularly, the unrighted acid that is applicable in the present invention using can be selected from and comprise 18 aliphatic acid to 22 carbon atoms, particularly poly-unrighted acid, especially omega-fatty acid and ω-6 aliphatic acid.
In composition of the present invention in the poly-unrighted acid of operable ω-6 series, that especially can mention has: contain the undersaturated linoleic acid of 18 carbon atoms and two places (18:2 ω-6), contain the undersaturated gamma-Linolenic acid of 18 carbon atoms and three places (18:3 ω-6), contain the undersaturated dihomo-gamma-linolenic acid of 20 carbon atoms and three places (20:3 ω-6), arachidonic acid, 5,8,11,14-eicosatetraenoic acid (20:4 ω-6) and docosatetraenoic acid (22:4, ω-6).
The undersaturated aliphatic acid of ω-3 series can especially be selected from: alpha-linolenic acid (18:3 ω-3), parinaric acid (18:4 ω-3), 5,8,11,14,17-eicosapentaenoic acid or EPA(20:5 ω-3), 4,7,10,13,16,19-DHA or DHA(22:6 ω-3), clupanodonic acid (22:5 ω-3) and normal-butyl-5,11,14-docosatrienoic acid.
Alpha-linolenic acid, gamma-Linolenic acid, parinaric acid, eicosapentaenoic acid, DHA, they mixture or comprise that these sour extracts are particularly suitable for using in the present invention.
The source of gamma-Linolenic acid can be selected from vegetable oil, for example, the extract of evening primrose oil, borage oil, currant nut oil, blueweed (Ecchium) oil and hemp-seed oil and micro-algae spiral algae (spirulina maxim (Spirulina maxima) and blunt top spirulina (Spirulina platensis)).
For example, from the vegetable oil of walnut, fibert, almond (Juglans regia), coriander, soybean (Glycina max), rapeseed (Brassica naptus), chia, flax, musk rose and fish oil, be rich in the poly-unrighted acid of ω-3 series.The poly-unrighted acid in ω-3 can also be found in zooplankter, shell-fish/mollusk and fish.
Fish oil is the key industry source of EPA and DHA.
Micro-algal biomass can also be configured for extracting the material of omega-3 unsaturated fatty acid.
Therefore, in composition of the present invention, the form of operable poly-unrighted acid is selected from least one oil of following oils: evening primrose oil, borage oil, currant nut oil, walnut oil, soya-bean oil, fish oil, sunflower oil, wheat-germ oil, hemp-seed oil, fenugreek oil, musk rose oil, blueweed oil, Morocco's macadamia nut oil, monkey-bread tree oil (baobab oil), rice bran oil, sesame oil, apricot kernel oil, walnut oil, hazelnut oil, chia seed oil, linseed oil, musk rose oil, olive oil, avocado oil, safflower oil, coriander oil and/or from micro-algal biomass (for example, spirulina) the middle oil that extracts or extract from zooplankter.
According to an embodiment, composition of the present invention can comprise other hydrophilic active agent.Operable hydrophilic active agent comprises protein or protein hydrolysate, amino acid, polyalcohol (especially C 2to C 10alcohol, for example, glycerine, sorbierite, butanediol or polyethylene glycol), urea, allantoin, sugar and sugar derivatives, water soluble vitamin, starch, and bacterial extract or plant extracts (for example, from aloe (Aloe vera) extract).
According to another embodiment, composition of the present invention can also comprise lipophile activating agent.
Operable lipophile activating agent comprises retinol (vitamin A) and derivative, tocopherol (vitamin E) and derivative, ceramide and essential oil.
According to activating agent of the present invention can also be especially intended to for preventing and/or treating the combination of dermopathic activating agent.
According to another embodiment, can also use activating agent:
-the interior of its participation corium gathers, for example, and gucosamine, rosemary, Xue MingRosma rinus officinalis, carnitine, blueberry, Salvia japonica (sage), spinach, strawberry, green coffee or apple,
-its auxiliary cell upgrades, for example biostearin and plant hormone (for example, Daidzein or diosgenin),
-anti-inflammatory compound, for example aurantiamarin or lactoferrin,
-agents for defoliating (pro-desquamating agent),
-antioxidant,
-anti-fat the agent of overflowing,
-antibacterials, for example antibiotic, for example, erythromycin.
Method
According on the other hand, the present invention relates to a kind of skin complexion and/or relevant aesthetic dermopathic oral beauty method of being used for the treatment of, according to the routine techniques for these cosmetic compositions, it especially can use as cosmetic composition defined above by using.
According to an embodiment, the present invention relates to a kind of for preventing and/or treating the oral beauty method of individual skin complexion defect needing, described method comprise to described individuality be applied to few effective dose monounsaturated fatty acids (particularly petroselic acid), its salt and/or its ester and at least one step.
The method according to this invention can comprise the step of observing the minimizing of skin complexion defect or even disappearing.
According to an embodiment, method of the present invention can preferably be applied to older individuals, adult female, have skin individual of Asian's type or have the individuality of the skin of African's type.
Advantageously, the application of method of the present invention can reduce or even eliminate skin blemishes, and preferably from the skin blemishes of skin of face, recovers uniform, the consistent colour of skin and/or do not have the colour of skin of dim outward appearance and promote to form the glossiness colour of skin.
Especially can carry out according to beauty method of the present invention by the food compositions of using as above limited.
Method of the present invention can be carried out every day, for example, for example, with the frequency of using once or use for one day twice (, morning last time and evening are once) every day, carries out.
According to beauty method of the present invention, can be undertaken by oral administration, for example, by the composition that every day, administration was prepared, according to enough amount and the number of times of form administration every day of the composition of preparation, for example, form is gel capsule, gel, lotion, sugar coated tablet, emulsion, tablet, capsule or bottle oral liquid (drinkable vials).
The monounsaturated fatty acids of effective dose can every day single dose or the dosage several times in one day, for example, twice to three times of every day.
The method according to this invention preferably includes single-dose.
Beauty method of the present invention can be at one week to several weeks or even carry out in time period of several months, and this time period can repeat to continue several months or several years even after the untreated time period.
For example, according to using of activating agent of the present invention can be conventionally at least 4 weeks or even in 4 weeks to 15 weeks long-time section for example every day 2 times to 3 times or more times repeat, in situation suitably, stop using a time period or multiple time period.
Oral beauty method can be at one week to several weeks or even carry out in time period of several months, in addition, this time period can repeat to continue several months or several years even after the untreated time period.
For example, can be in common at least 4 weeks or even with for example, every day, the frequency of 3 times was carried out in 4 weeks to 15 weeks long-time section according to the oral administration of monounsaturated fatty acids of the present invention, this long-time section comprises one or more down time sections or repetition down time section after alternatively.
The specific embodiment
In this description and embodiment below, unless otherwise indicated, otherwise percentage is weight percentage and with " ... and ... between " the scope of value of form statement comprise described lower limit and the upper limit.Before preparation, in order and under those skilled in the art can easily definite condition, composition is admixed together.
Following examples illustrate as non-limitative illustration of the present invention.
embodiment
embodiment 1
Orally administered composition
embodiment 1A: powder rod
Active component ?
Lactobacillus paraceasi ST11 10 10cfu
Lactic acid Bifidobacterium Bb12 10 10cfu
Calcium citrate 50mg
Petroselic acid 100mg
? ?
Excipient ?
Xanthans 0.8mg
Sodium Benzoate 0.2mg
Maltodextrin Complement to 30g
Within one day, can take a rod.
Taking such rod every day continues can make skin have the uniform and shinny colour of skin in approximately 1 week.
embodiment 1B: powder rod
active component ?
magnesium gluconate 50
lactobacillus paraceasi ST11 5 × 10 .cfu
lactic acid Bifidobacterium Bb12 5 × 10.Cfu
calcium citrate 200
coriander oil 250
? ?
excipient ?
xanthans 0.8 mg
sodium Benzoate 0.2 mg
maltodextrin complement to 30g
Within one day, can take a rod.
Taking such rod every day continues within approximately one week, can obviously reduce dermatodyschroia and make skin present even, the luminous and glossiness colour of skin.
embodiment 1C: capsule
Active component Mg/ capsule
Coriander oil 150
Vitamin C 60
Dolomol 0.02
Can take one to three such capsule every day.
Taking such capsule every day continues can obviously reduce for approximately one week dermatodyschroia, rubescent and skin defect and makes skin present uniform, luminous and the glossiness colour of skin.
embodiment 1D: the preparation of sugar coated tablet type
Active material Mg/ coating tablet
Coriander oil 550
? ?
The excipient of the core of coating tablet ?
Microcrystalline cellulose 70
Encompress TM 60
Dolomol 3
Anhydrous silica gel 1
? ?
Coating agent ?
Shellac 5
Talcum powder 61
Sucrose 250
PVP 6
Titanium dioxide 0.3
Colouring agent 5
The sugar coated tablet of taking the type can every day 1 time to 3 times.
Taking such sugar coated tablet every day continues within approximately one week, can obviously reduce dermatodyschroia and skin defect and can make skin have even, the shinny and glossiness colour of skin.
embodiment 1E: the preparation of sugar coated tablet type
Active material Mg/ coating tablet
Coriander oil 250
Yue Shi lactobacillus 10 9cfu
? ?
The excipient of the core of coating tablet ?
Microcrystalline cellulose 70
Encompress TM 60
Dolomol 3
Anhydrous silica gel 1
? ?
Coating agent ?
Shellac 5
Talcum powder 61
Sucrose 250
PVP 6
Titanium dioxide 0.3
Colouring agent 5
The coating tablet of taking the type can every day 1 time to 3 times.
Taking such coating tablet every day continues within approximately one week, can obviously reduce dermatodyschroia and skin defect and can make skin have even, the shinny and glossiness colour of skin.

Claims (11)

1. the oral use of at least one monounsaturated fatty acids of effective dose, its salt and/or its ester or nutrition beautifying use, described monounsaturated fatty acids, its salt and/or its ester be as treating and/or preventing the activating agent of skin complexion defect, described defect be not the damage that produced by inflammatory phenomena, irrelevant with melanic excessive generation, be not skin surface defect and be not that the brightness of skin complexion lacks.
2. according to the purposes described in last claim, described monounsaturated fatty acids, its salt and/or its ester are for preventing and/or treating the skin of fuzzy skin, dim skin, colour of skin inequality or tool skin defective or dermatodyschroia and/or for representing the gloss of the colour of skin.
3. purposes according to claim 1 and 2, wherein, described skin is facial skin, the skin of neck and/or the skin of neckline position, and skin of face preferably.
4. according to purposes in any one of the preceding claims wherein, wherein, described monounsaturated fatty acids, its salt and/or its ester are the form of separation or the form of plant extracts.
5. according to purposes in any one of the preceding claims wherein, wherein, described monounsaturated fatty acids, its salt and/or its ester are used in Orally administered composition, and the content of wherein said monounsaturated fatty acids, its salt and/or its ester is: daily dose is in the scope from 0.5mg/ days to 2500mg/ days, and especially in the scope from 5mg/ days to 500mg/ days.
6. according to purposes in any one of the preceding claims wherein, wherein, described monounsaturated fatty acids is petroselic acid.
7. according to the purposes described in last claim, wherein, described petroselic acid is to be used from samphire or from the oily form of safflower geranium wilfordii.
8. according to the purposes described in last claim, wherein, described samphire grease separation is from coriander seed oil, tuberous chervil seed oil, carrot seed seed oil, celery seed oil, cumin seed oil, Caraway seed oil, parsley seed oil, dill seed oil and their mixture.
9. according to purposes in any one of the preceding claims wherein, wherein, described monounsaturated fatty acids and the cosmetic activity agent that at least one is other are used in combination, described at least one other cosmetic activity agent is especially selected from vitamin B3, vitamin B5, pyridoxamine, VB8, vitamin C, vitamin E or nicotinic acid, carotenoid, curcuminoids, nicotinic acid, flavonoids, one or more divalence mineral cations, bacterium or derive from non-photosynthetic, non-solid hyphomycetic bacterial extract, probiotic micro-organisms, especially lactic microorganisms, the mixture of the mixture of probiotic nutrient or probiotic micro-organisms and/or probiotic nutrient.
10. according to the purposes described in last claim, wherein said probiotic micro-organisms is selected from Lactobacillus and/or Bifidobacterium, its part and/or its metabolin.
11. 1 kinds of oral cosmetic treatments, described method is used for the treatment of and/or prevents the individual skin complexion defect of needs, described method comprises at least one step of described individuality being used at least one monounsaturated fatty acids, its salt and/or its ester of effective dose, described defect be not the damage that produced by inflammatory phenomena, irrelevant with melanic excessive generation, be not skin surface defect and be not that the brightness of skin complexion lacks.
CN201180064169.8A 2010-11-05 2011-11-03 Monounsaturated fatty acid for preventing and/or treating skin complexion imperfections Pending CN103747692A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1059144 2010-11-05
FR1059144A FR2967070B1 (en) 2010-11-05 2010-11-05 MONOINSATURE FATTY ACID FOR PREVENTING AND / OR TREATING SKIN DUST IMPERFECTIONS
PCT/IB2011/054895 WO2012059880A1 (en) 2010-11-05 2011-11-03 Monounsaturated fatty acid for preventing and/or treating skin complexion imperfections

Publications (1)

Publication Number Publication Date
CN103747692A true CN103747692A (en) 2014-04-23

Family

ID=43989810

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180064169.8A Pending CN103747692A (en) 2010-11-05 2011-11-03 Monounsaturated fatty acid for preventing and/or treating skin complexion imperfections

Country Status (10)

Country Link
US (1) US9730905B2 (en)
EP (1) EP2635140A1 (en)
CN (1) CN103747692A (en)
BR (1) BR112013011064A2 (en)
CA (1) CA2816732C (en)
CL (1) CL2013001232A1 (en)
FR (1) FR2967070B1 (en)
MX (1) MX353580B (en)
RU (1) RU2013120495A (en)
WO (1) WO2012059880A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107427461A (en) * 2015-01-14 2017-12-01 婴幼儿细菌治疗公司 The method for activating lactic acid bacteria

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2982150B1 (en) 2011-11-09 2016-05-20 Oreal MONO-UNSATURATED FATTY ACID FOR NAIL CARE
FR3005411B1 (en) 2013-05-07 2016-09-30 Laboratoires Inneov ASSOCIATION OF ACTIVE INGREDIENTS FOR ORAL ADMINISTRATION TO ENHANCE THE QUALITY OF NAILS.
FR3005410A1 (en) * 2013-05-07 2014-11-14 Inneov Lab PETROSELINIC ACID AND ZINC ASSOCIATION FOR ORAL ADMINISTRATION TO COMBAT HAIR AGING
JP6204174B2 (en) * 2013-12-10 2017-09-27 日清ペットフード株式会社 Pet food
WO2015121455A1 (en) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprising at least one probiotic

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0709084A2 (en) * 1994-10-07 1996-05-01 L'oreal Use of an oil rich in petroselinic acid as hydrating agent
WO1999047110A1 (en) * 1998-03-16 1999-09-23 Unilever Plc Cosmetic method of treating skin
EP1013178A1 (en) * 1998-12-22 2000-06-28 Loders Croklaan B.V. Petroselinic acid and its use in food, fat compositions containing petroselinic acid
CN1365272A (en) * 1999-07-30 2002-08-21 荷兰联合利华有限公司 Skin care composition containing petroselinic acid
WO2008078050A2 (en) * 2006-12-14 2008-07-03 L'oreal Use of at least one mono-unsaturated fatty acid for the treatment of fragile skin, mucous or semi-mucous tissues and scalp
CN101646415A (en) * 2006-12-14 2010-02-10 欧莱雅公司 At least a monounsaturated fatty acid is used to improve the oral use of hair

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38141E1 (en) * 1997-10-17 2003-06-10 International Flora Technologies Ltd. Dry emollient compositions
CA2382670A1 (en) * 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0709084A2 (en) * 1994-10-07 1996-05-01 L'oreal Use of an oil rich in petroselinic acid as hydrating agent
WO1999047110A1 (en) * 1998-03-16 1999-09-23 Unilever Plc Cosmetic method of treating skin
EP1013178A1 (en) * 1998-12-22 2000-06-28 Loders Croklaan B.V. Petroselinic acid and its use in food, fat compositions containing petroselinic acid
CN1365272A (en) * 1999-07-30 2002-08-21 荷兰联合利华有限公司 Skin care composition containing petroselinic acid
WO2008078050A2 (en) * 2006-12-14 2008-07-03 L'oreal Use of at least one mono-unsaturated fatty acid for the treatment of fragile skin, mucous or semi-mucous tissues and scalp
CN101646415A (en) * 2006-12-14 2010-02-10 欧莱雅公司 At least a monounsaturated fatty acid is used to improve the oral use of hair

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TSEVEGSUREN N ET AL: "Geranium sanguineum (Geraniaceae) seed oil: a new source of petroselinic and vernolic acid", 《LIPIDS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107427461A (en) * 2015-01-14 2017-12-01 婴幼儿细菌治疗公司 The method for activating lactic acid bacteria

Also Published As

Publication number Publication date
BR112013011064A2 (en) 2016-07-19
CA2816732C (en) 2020-02-18
FR2967070A1 (en) 2012-05-11
CA2816732A1 (en) 2012-05-10
US9730905B2 (en) 2017-08-15
MX353580B (en) 2018-01-19
FR2967070B1 (en) 2013-07-05
US20130302297A1 (en) 2013-11-14
CL2013001232A1 (en) 2013-12-20
EP2635140A1 (en) 2013-09-11
RU2013120495A (en) 2014-12-10
MX2013005025A (en) 2013-06-03
WO2012059880A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
EP2306970B1 (en) Cosmetic use of Lactobacillus paracasei for the treatment of oily skin
CN102131495B (en) Microorganism is used to treat the cosmetic applications of scalp illness
CN1712022B (en) Process and compositions for the protection and/or the treatment of dry and/or sensitive skin
CN104188888A (en) Probiotic microorganisms as an active ingredient for enhancing skin radiance
CN104822363B (en) The combination of at least one polyunsaturated fatty acid and at least one carotenoid is used for the purposes for improving nail quality
CN103747692A (en) Monounsaturated fatty acid for preventing and/or treating skin complexion imperfections
CN102762194A (en) Probiotic microorganisms as active agents against changes in the skin's microrelief
CN103998020B (en) Monounsaturated fatty acid for manicure
ES2574559T3 (en) Use of petroselinic acid for the treatment of fragile scalps
US11147302B2 (en) Use of a combination of taurine or a derivate thereof and a grape extract for improving the quality of the nails
CN105960229A (en) Orally administered composition based on polyunsaturated fatty acid and vitamin d for improving hair quality

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140423